Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SelK2 in Asthma and COPD
NCT04540042Phase 2Completed
- Sponsor
- Tetherex Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SelK2 in asthma, chronic obstructive pulmonary disease (COPD), sponsored by Tetherex Pharmaceuticals. Started Aug 2020; status: completed.
02
Drugs
SelK2
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04540042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540042.